Page 7 - Diabetes

Besides Covid-19, diabetes and renal disease reduce Indian lifespan

Covid-19 was the leading cause of death in India, as per the study. The age-standardised rate of deaths for both males and females was 156.8 per 100,000 population

Preventive online health checkups rise 50% in India: Simpl Checkout Scan

Lifestyle-based checkups including diabetes, vitamin deficiency and hair fall, apart from comprehensive full-body checkups, are the most preferred by Indians

Non-Covid deaths high in people with diabetes, women affected more: Study

Non-Covid-related deaths increased among people having diabetes because of pandemic-related disruptions, new research published in The Lancet Diabetes and Endocrinology journal has found. The global review of studies comparing pre-pandemic and during-pandemic data found that the complication of sight loss in people with diabetes also increased. The negative impacts were most pronounced for women, younger people and racial and ethnic minority groups, it found. The team of researchers, including those from the World Health Organization (WHO), looked at 138 studies - North America (39), Western Europe (39), Asia (17) and others from Eastern Europe, South America, Egypt, Australia and multiple regions - to examine the impacts of pandemic-related disruptions on the vulnerable diabetic population. The research findings pointed to the importance of ensuring that all people with diabetes, especially those from the less advantaged groups, had consistent access to diabetes medication and care

Glenmark cuts diabetes drug cost by 70% with first Indian biosimilar launch

Drug, marketed under the brand name Lirafit, is priced at approximately Rs 100 for a standard daily dose of 1.2 mg

Glenmark Pharmaceuticals launches antidiabetic drug 'Lirafit' in India

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

50% surge in diabetes in individuals under 40 yrs of age, say experts

India is often dubbed as the diabetic capital of the world where nearly 11 per cent of the population is grappling with the disease

Karwa Chauth: All you need to know about fasting tips for diabetic women

Karwa Chauth is a delightful and sacred Hindu Celebration. In India, particularly in Northern parts of India, women fast from sunrise to moonrise for the well-being and long life of their spouses

Prefer deductible to co-pay in senior citizen health insurance cover

Last week Tata AIG General Insurance launched a plan for this group, adding to the considerable number of plans already available

Biocon, Juno Pharma ink pact for commercialisation of Liraglutide in Canada

Under the agreement's terms, Biocon will be responsible for obtaining regulatory approvals for Liraglutide and will subsequently manage the manufacturing and distribution of the product within Canada

Natural light may help treat and prevent type 2 diabetes: Research

Exposure to natural light may help treat and prevent type 2 diabetes, according to a small study. The research, presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Germany from October 2-6, carried out a range of metabolic tests on a group of people with type 2 diabetes when they were exposed to natural light and when they were exposed to artificial light and compared the results. "The misalignment of our internal circadian clock with the demands of a 24/7 society is associated with an increased incidence of metabolic diseases, including type 2 diabetes," said Ivo Habets of Maastricht University, the Netherlands, who co-led the research. "Natural daylight is the strongest zeitgeber, or environmental cue, of the circadian clock, but most people are indoors during the day and so under constant artificial lighting," said Habets. The yet-to-be peer-reviewed study involved 13 participants with an average age of 70 years who stayed in research

Implantable device could allow injection-free diabetes management: Study

The study was published in Proceedings of the National Academy of Science

Dr Reddy's Lab launches generic diabetes medication in US market

Dr Reddy's Laboratories on Thursday said it has launched a generic diabetes medication in the US market. The drug major has launched Saxagliptin and Metformin Hydrochloride extended-release tablets in the US market, the Hyderabad-based company said in a statement. The company's product is a therapeutic equivalent generic version of Kombiglyze XR tablets, it added. Dr Reddy's Saxagliptin and Metformin Hydrochloride extended-release tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30, the company said.

Akums Drugs gets DCGI nod for triple combination diabetes medication

Akums Drugs and Pharmaceuticals on Thursday said it has received approval from the Drug Controller General of India (DCGI) for triple combination diabetes medication. Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500 have been combined for the treatment of diabetes and offers a number of pharmacological advantages, the company said in a statement. The combination drug is going to better serve anti-diabetic patients, who require better treatment without necessarily swallowing multiple drugs. Akums Drugs & Pharmaceuticals Joint Managing Director Sandeep Jain noted that the renoprotective effects of drugs like metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solution for diabetes. "As a brand, we will continue to introduce new combinations to help patients around the world get better," he added.

Deep sleep improves body's response to insulin, key to regulate blood sugar

An increased responsiveness of the human body to insulin during deep sleep, in turn, improving blood sugar control the next day, may be why lack of quality sleep is considered to increase risk of diabetes, researchers say. A stronger and a more frequent linking of the deep sleep brain waves, particularly the sleep spindles and the slow waves, triggered the body's parasympathetic nervous system into action, the researchers from the University of California (UC) Berkeley, US, found after examining sleep data of 600 individuals. The parasympathetic branch of the nervous system is associated with soothing and calming the body by producing physiological effects such as slowing down the heart and dilating blood vessels. The researchers detected this shift in the participants by measuring changes in their heart rate. Further, they found that switching to this tranquil and calm mode enhanced the body's responsiveness to insulin, the blood sugar-regulating hormone, which instructs cells to

Medicines for anxiety, diabetes to get cheaper as NPPA fixes ceiling prices

If drug manufacturers are found flouting the ceiling, they will have to deposit the overcharged amount with the Centre

Diabetes a pandemic, needs vaccines, efficacious medication for control

It is estimated that 101 million people in India - around 10 per cent of the country's population - are suffering from diabetes

Want immediate insurance coverage for diabetes? Apply for a customised plan

Though costlier, they offer coverage for both type I and II diabetes, and to those with high levels of HbA1C

Race to develop weight-loss pills has some drugmakers falling behind

Novo and Lilly's experimental obesity pills helped people lose about 15% of body weight, similar to weight-loss shots on the market already, according to findings presented

Pfizer to discontinue development of obesity drug due to side effects

Pfizer has been developing treatments to target weight loss in diabetes and obesity patients, as it races to target a market estimated to reach $100 billion by the end the of decade

Eli Lilly's Mounjaro gives positive results in obese diabetic people

Diabetes occurs when the body loses the ability to control blood sugar, and it's one of the world's most common serious diseases